CA2099772A1 - Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih - Google Patents

Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih

Info

Publication number
CA2099772A1
CA2099772A1 CA002099772A CA2099772A CA2099772A1 CA 2099772 A1 CA2099772 A1 CA 2099772A1 CA 002099772 A CA002099772 A CA 002099772A CA 2099772 A CA2099772 A CA 2099772A CA 2099772 A1 CA2099772 A1 CA 2099772A1
Authority
CA
Canada
Prior art keywords
composition
sterol
weight
nystatin
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002099772A
Other languages
English (en)
Inventor
Gabriel Lopez-Berestein
Reeta Mehta
Prem Sarin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2099772A1 publication Critical patent/CA2099772A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CA002099772A 1991-01-14 1992-01-03 Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih Abandoned CA2099772A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64069491A 1991-01-14 1991-01-14
US640,694 1991-01-14
PCT/US1992/000057 WO1992011841A1 (fr) 1991-01-14 1992-01-03 Activite anti-vih de la nystatine liposomale et de l'amphotericine b

Publications (1)

Publication Number Publication Date
CA2099772A1 true CA2099772A1 (fr) 1992-07-15

Family

ID=24569326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002099772A Abandoned CA2099772A1 (fr) 1991-01-14 1992-01-03 Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih

Country Status (5)

Country Link
EP (1) EP0567559A1 (fr)
JP (1) JPH06509058A (fr)
AU (1) AU1201192A (fr)
CA (1) CA2099772A1 (fr)
WO (1) WO1992011841A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525468A1 (fr) * 2003-05-12 2004-11-25 Novosom Ag Reserves injectables constituees d'agregats liposomaux pour l'administration de principes actifs
EP4322963A1 (fr) * 2021-04-16 2024-02-21 Pannonpharma Gyógyszergyártó Kft. Traitement d'une infection virale avec un antibiotique macrolide polyénique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5032404A (en) * 1989-02-23 1991-07-16 Board Of Regents, The University Of Texas System Lipsome-incorporation of polyenes

Also Published As

Publication number Publication date
WO1992011841A1 (fr) 1992-07-23
EP0567559A1 (fr) 1993-11-03
AU1201192A (en) 1992-08-17
JPH06509058A (ja) 1994-10-13

Similar Documents

Publication Publication Date Title
Magnani et al. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies.
JP2825804B2 (ja) 抗原を導入したリポソーム
EP0296212A1 (fr) Liposomes presentant une duree de circulation prolongee.
JPH02502459A (ja) リポソーム含有ニスタチン
JPH02501576A (ja) 新規な抗レトロウイルス剤および供給系
Dufresne et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab′ fragments
JPH06501680A (ja) 生体内の自己以外の細胞を排除するオートバイオチクスおよびそれらの使用
Machy et al. Freezing of liposomes
Pontani et al. Inhibition of HIV replication by liposomal encapsulated amphotericin B
EP1581187A2 (fr) Compositions et methodes associees aux formulations de lipide:emodine
Désormeaux et al. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2', 3'-dideoxyinosine
CA2099772A1 (fr) Composition liposomique a base de nystatine et d'amphotericine b presentant une activite anti-vih
EP0552280B1 (fr) Inhibition de replication virale
EP0183352A2 (fr) Utilisation de suramine pour clinothérapie des infections par quelques-uns des membres de la famille des virus humains leucémiques de cellules-T (HTLV) y compris le virus lymphadénopathique (LAV)
Szoka Jr et al. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes
US20070026061A1 (en) Liposomal formulation and use thereof
Schwendener et al. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens
US20130085146A1 (en) Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
Crews et al. Lipids are major components of human immunodeficiency virus (HIV): Modification of HIV lipid composition, membrane organization, and protein conformation by AL‐721®
Vertut-Croquin et al. Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability
北川均 et al. Canine dirofilarial hemoglobinuria induced by milbemycin D administration.
RU2203071C2 (ru) Применение белков в качестве антиретровирусных агентов
WO1989005152A1 (fr) Procede et composition anti-virale encapsulee dans des liposomes
JPH0474116A (ja) リポソーム
Abbas et al. Efficacy of Amphotericine B Ddrug Against Promastigote and Axenic Amastigote of Leishmania Dononvani in Vitro

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19960703